Did CEOs and officers buy or sell their own stock?
Open-market trades by the people who know the company best, with their own money.
Last 7 days: the stocks insiders bought and sold most
Stocks Koreans hold most · disclosed Last 7 days · open-market trades only
Bought most
Sold most
Whalegun
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Edgewise TherapeuticsEWTX | Open-market sale | 05/04–05/05 | 05/05 | 55,230 sh2 trades | $37.88avg. | $2,092,146.7 | −92.7% | |
Edgewise TherapeuticsEWTX | Open-market sale10b5-1 plan | 04/01 | 04/02 | 28,662 sh | $32.31 | $926,069.22 | −74.9% | |
Edgewise TherapeuticsEWTX | Open-market sale10b5-1 plan | 03/31 | 03/31 | 21,338 sh | $32.12 | $685,376.56 | −69.0% | |
Edgewise TherapeuticsEWTX | Open-market sale10b5-1 plan | 03/27 | 03/30 | 16,358 sh2 trades | $30.98avg. | $506,770.84 | −63.0% | |
Edgewise TherapeuticsEWTX | Open-market sale10b5-1 plan | 01/21 | 01/23 | 115,471 sh5 trades | $29.44avg. | $3,399,466.24 | −85.4% | |
Alan J. RussellChief Scientific Officer | Edgewise TherapeuticsEWTX | Open-market sale | 25/11/12 | 25/11/13 | 100,000 sh | $21.12 | $2,112,000 | −81.0% |
Jonathan C. FoxDirector | Edgewise TherapeuticsEWTX | Open-market buy | 25/11/11 | 25/11/13 | 10,700 sh | $18.64 | $199,448 | +82.3% |
Alan J. RussellChief Scientific Officer | Edgewise TherapeuticsEWTX | Open-market sale | 25/08/26 | 25/08/28 | 100,000 sh | $14.60 | $1,460,000 | −81.0% |
Kevin KochPresident and CEO | Edgewise TherapeuticsEWTX | Open-market sale | 25/08/12 | 25/08/14 | 7,972 sh | $13.39 | $106,745.08 | −20.7% |
John R. MooreGeneral Counsel | Edgewise TherapeuticsEWTX | Open-market sale | 25/08/12 | 25/08/14 | 2,098 sh | $13.39 | $28,092.22 | −17.0% |
Edgewise TherapeuticsEWTX | Open-market sale | 25/08/12 | 25/08/14 | 2,862 sh | $13.39 | $38,322.18 | −10.1% | |
Edgewise TherapeuticsEWTX | Open-market sale | 25/08/12 | 25/08/14 | 1,428 sh | $13.39 | $19,120.92 | −1.6% | |
Behrad DerakhshanChief Business Officer | Edgewise TherapeuticsEWTX | Open-market sale | 25/08/12 | 25/08/14 | 2,491 sh | $13.39 | $33,354.49 | −9.5% |
Alan J. RussellChief Scientific Officer | Edgewise TherapeuticsEWTX | Open-market sale | 25/08/12 | 25/08/14 | 1,907 sh | $13.39 | $25,534.73 | −7.5% |
Kevin KochPresident and CEO | Edgewise TherapeuticsEWTX | Open-market sale | 25/05/02 | 25/05/07 | 4,276 sh | $16.45 | $70,340.2 | −17.2% |
John R. MooreGeneral Counsel | Edgewise TherapeuticsEWTX | Open-market sale | 25/05/02 | 25/05/07 | 1,930 sh | $16.45 | $31,748.5 | −22.8% |
Edgewise TherapeuticsEWTX | Open-market sale | 25/05/02 | 25/05/07 | 5,187 sh | $16.45 | $85,326.15 | −19.4% | |
Edgewise TherapeuticsEWTX | Open-market sale | 25/05/02 | 25/05/07 | 1,314 sh | $16.45 | $21,615.3 | −1.6% | |
Behrad DerakhshanChief Business Officer | Edgewise TherapeuticsEWTX | Open-market sale | 25/05/02 | 25/05/07 | 1,691 sh | $16.45 | $27,816.95 | −7.7% |
Alan J. RussellChief Scientific Officer | Edgewise TherapeuticsEWTX | Open-market sale | 25/05/02 | 25/05/07 | 1,551 sh | $16.45 | $25,513.95 | −7.7% |